Carbohydrates as T cell-activating antigens have been generating significant interest. For many years, carbohydrates were thought of as T-independent antigens, however, more recent research had demonstrated that mono-or oligosaccharides glycosidically linked to peptides can be recognized by T cells. T cell recognition of these glycopeptides depends on the structure of both peptide and glycan portions of the antigen. Subsequently, it was discovered that natural killer T cells recognized glycolipids when presented by the antigen presenting molecule CD1d. A transformative insight into glycan-recognition by T cells occurred when zwitterionic polysaccharides were discovered to bind to and be presented by MHCII to CD4+ T cells. Based on this latter observation, the role that carbohydrate epitopes generated from glycoconjugate vaccines had in activating helper T cells was explored and it was found that these epitopes are presented to specific carbohydrate recognizing T cells through a unique mechanism. Here we review the key interactions between carbohydrate antigens and the adaptive immune system at the molecular, cellular and systems levels exploring the significant biological implications in health and disease.
Introduction
The mammalian immune system continually interacts in many ways with microbes and environmental agents composed of biologically complex molecules. Research has traditionally focused on how immune cells interact with proteins, paying comparatively little attention to other prominent biologic molecules such as carbohydrates, which decorate the surface of nearly all microbial classes. The relative lack of interest in immunology research on carbohydrate antigens has been due mainly to their inability to induce an adaptive immune response. With recent advances in analytical and biochemical research tools, we now have a better understanding of the important interactions of carbohydrate antigens with the adaptive arm of the immune system. Carbohydrate-containing antigens include glycolipids, which are presented to T cells by CD1 [1] ; glycopeptides containing mono-or oligosaccharides, which are generated by processing of natural glycoproteins [2] ; zwitterionic polysaccharides (ZPSs) that activate T cells [3, 4] ; and glycoconjugate vaccines [5] . In this article, we review key interactions of carbohydrate-containing antigens with the adaptive immune system and the biological implications of these interactions.
Zwitterionic polysaccharides
ZPSs, which have alternating positive and negative charges in each repeating unit, are taken up by antigen-presenting cells (APCs), processed through oxidative reactions by the major histocompatibility class II (MHCII) pathway, and presented to T cells in the context of MHCII [3, 6] . Their zwitterionic motif allows ZPSs processed in the endosome to bind to MHCII, primarily by electrostatic interactions [7] . After ZPS presentation, CD4+ T cells can recognize and respond specifically to these carbohydrates [8, 9] . Non-zwitterionic polysaccharides, which have only negatively charged residues or no charge groups at all, make up the majority of microbial carbohydrates [4, 10] . Of the non-zwitterionic polysaccharides examined to date, all are processed in the endosome by oxidative mechanisms [6] but fail to bind to MHCII and therefore cannot be presented to or activate T cells. Therefore, non-zwitterionic polysaccharides have been considered T cellindependent antigens [4, [11] [12] [13] [14] . Polysaccharide A (PSA), which is expressed on the surface of the gram-negative symbiotic bacterium Bacteroides fragilis, is so far the most-studied ZPS. Other ZPSs that have been widely studied include Streptococcus pneumoniae type 1 polysaccharide [15] [16] [17] and Staphylococcus aureus type 5 and type 8 polysaccharides [18, 19] . PSA elicits T-cell responses critical to immunologic development [20, 21] and to protection against inflammatory diseases such as inflammatory bowel disease (IBD) [22] .
Studies in our laboratory established the mechanisms for T-cell activation by PSA [3, 6] . Through a series of confocal microscopy and size-exclusion chromatography experiments, we first established that PSA is taken up by APCs and processed into smaller fragments in the endocytic compartments. We then discovered that processed PSA binds to MHCII proteins in endosomes and is presented on the surface of APCs. We showed that the MHCII-presented PSA epitope forms an immune synapse with the T-cell receptor (TCR) of CD4+ T cells. Moreover, we investigated the chemical reactions responsible for processing of PSA in the endocytic compartments [6] . We found that PSA is depolymerized in endosomes through deamination resulting from the action of reactive nitrogen species (RNSs) such as nitric oxide. We further observed that endosomal depolymerization of PSA depends on the upregulation of inducible nitric oxide synthase (iNOS), which is responsible for generation of RNSs [6] . Finally, we demonstrated that iNOS expression in APCs is required for PSA-induced CD4+ T-cell activation.
PSA exerts its immunological activity through multiple mechanisms [4, 23] . Earlier studies focused on the therapeutic and prophylactic roles of PSA in intraabdominal abscess formation [24] . PSA prevents the formation of abscesses by a T cell-dependent mechanism [24] [25] [26] . More specifically, PSA-activated splenic T cells prevented abscess induction by B. fragilis in mice. T cell-mediated protection against abscess formation was critically dependent on the zwitterionic charge motif of PSA. Elimination of negative or positive charges abolished PSA-mediated stimulation of T cells and, consequently, protection from abscess formation [27] .
Our research over the past two decades has substantiated the critical immunomodulatory roles of PSA in the context of the symbiotic relationship between the mammalian immune system and B. fragilis [4, 23] . In one study, we monocolonized germ-free mice with a wild-type, PSA-expressing strain of B. fragilis or with a mutant strain lacking PSA ( PSA); we then measured splenic CD4+ T-cell numbers to identify the role of PSA in maturation of the adaptive immune system [20] . Mice colonized with PSA-expressing B. fragilis had T-cell numbers similar to those in conventional mice. In contrast, mice monocolonized with the PSA strain had significantly lower numbers of T cells than did conventional mice. B. fragilis corrected for defective T-cell development in germ-free mice through expression of PSA. MHCII presentation of PSA by dendritic cells (DCs) stimulated naïve CD4+ T cells to correct Tcell deficiency in germ-free mice. Furthermore, colonization with a PSA expressing strain of B. fragilis restored normal Th1/Th2 balance from the Th2 skewed phenotype of germ-free mice. These observations, along with our other findings in this study, served as an important illustration of the immunomodulatory activities of symbiotic bacteria residing in the gastrointestinal tract. In a separate study, we assessed the role of PSA in protection from IBD [22] , demonstrating that both PSA-expressing B. fragilis and purified PSA protected mice from colitis induced by Helicobacter hepaticus and that PSA-mediated protection was attributable to interleukin (IL) 10 produced by PSA-activated CD4+ T cells. Subsequent work has shown that PSA activates CD4+ CD25+ FoxP3+ regulatory T cells to secrete IL-10.
In short, PSA is one example of an immunomodulatory molecule produced by an important commensal bacterial resident of the gastrointestinal tract. It would be unduly pessimistic to think that there are no other bacterial products that help train our immune system for its maturation. Studies of the human microbiome, which have only recently become trendy, will shed light on the complex and beneficial relationship between human hosts and their bacterial inhabitants.
Glycoconjugate vaccines
On the basis of the successful use of the hapten-carrier protein conjugation strategy [28, 29] , it has become standard practice to couple capsular polysaccharides (CPSs) from bacterial targets to T cell-dependent carrier proteins to form glycoconjugate vaccines [30] [31] [32] [33] . Immunization with glycoconjugates, as opposed to pure polysaccharides, elicits T-cell help for B cells that produce IgG antibodies to the polysaccharide component [4, 34] . In addition to inducing polysaccharide-specific IgM-to-IgG switching, glycoconjugate immunization induces memory B-cell development and T-cell memory [4] . Immunizations with glycoconjugates containing CPSs from Haemophilus influenzae, Streptococcus pneumoniae, and Neisseria meningitidis have been highly successful in preventing infectious diseases in children caused by these virulent pathogens [33, 35] . The traditional explanation for the mechanism by which glycoconjugates induce humoral immune responses is that the carrier-protein portion of the conjugated vaccine stimulates CD4+ T cells, which, in turn, help B cells to secrete antibodies to glycans through a cognate interaction. Indeed, glycoconjugate vaccines have been developed on the assumption that eliciting a potent humoral response to bacterium-derived CPS requires coupling to a carrier protein that activates CD4+ T cells to help B cells produce the relevant antibodies [4, 13] . The traditional hypothesis of immune activation by glycoconjugate vaccines suggests that only a peptide generated from the glycoconjugate can be presented to and recognized by T cells. This view ignores the synthetic linkage of carbohydrates to proteins in glycoconjugates by extremely strong covalent bonds that are unlikely to be broken within the endosome. Thus the possibility of presentation of peptide bound carbohydrate to T cells is raised. Accordingly, we considered whether T cells can recognize non-zwitterionic carbohydrates (i.e., most CPSs) linked to another molecule (e.g., a peptide) whose binding to MHCII allows presentation of the linked hydrophilic carbohydrate on the APC surface.
In a recently published study, we uncovered the cellular and molecular mechanisms for adaptive immune responses mediated by glycoconjugate immunization [5] . We demonstrated that, upon uptake by APCs, glycoconjugate vaccines are involved in a depolymerization reaction that yields glycan-peptide -a processed glycan chemically bound to a peptide fragment. Glycan-peptide is displayed on the surface of APCs in the context of an MHCII protein ( Fig. 1 ). Our findings strongly suggest that the peptide portion of the glycan-peptide binds to MHCII and that the hydrophilic glycan is thereby exposed to the TCR of CD4+ T cells on the APC surface. Biochemical and structural analyses of the MHCII and TCR interactions of glycan-peptides will provide critical information about these interactions at the molecular level. We next showed that glycoconjugate immunization induces CD4+ T cells that recognize the carbohydrate portion of the vaccine (Fig. 1) . In this study, we isolated lymphocytes from mice immunized with GBSIII-OVA, a glycoconjugate consisting of the type III polysaccharide of group B Streptococcus (GBSIII) coupled to ovalbumin (OVA). We performed an ELISpot assay, co-culturing immune lymphocytes with irradiated syngeneic splenocytes derived from GBSIII-OVA-immunized mice (as APCs) in the presence of various antigens [5, 36] . We found that significantly more immune lymphocytes reacted with GBSIII-TT [GBSIII coupled to tetanus toxoid (TT)] than with either TT or GBSIII alone, with a consequently higher number of IL-2 spots. On the other hand, unconjugated OVA stimulated more immune lymphocytes than did GBSIII-TT [36] . These findings confirmed the presence among immune lymphocytes of T cells that recognize GBSIII as well as T cells that recognize OVA. Therefore, we decided to isolate carbohydrate-specific T cells from the immune lymphocytes. To eliminate OVA-specific T cells, the immune lymphocytes were restimulated with APCs in the presence of GBSIII-TT for an additional 10-14 days [36] . After cloning of immune CD4+ T cells by limiting dilution, the cloned cells were restimulated with GBSIII-OVA-pulsed APCs in culture medium containing the T-cell culture supplement [36] . Finally, we were able to isolate two distinct carbohydrate-specific CD4+ T-cell clones [5] : one recognizing GBSIII in the context of the I-A d molecule and the other recognizing GBSIII with the I-E d molecule [5] . Thus we provided irrefutable evidence for the presence of carbohydrate-specific CD4+ T cells, designated Tcarbs (Fig. 1 ). Since that study, we have established additional Tcarb clones [36] . Two distinct CD4+ T-cell clones secreted both IL-2 and IL-4, but not interferon ␥ (IFN-␥), in the presence of GBSIII conjugated to any of three carrier proteins: OVA, TT, or hen egg lysozyme [5] . However, none of the clones responded to the unconjugated carrier proteins alone. These data validated the existence of T cells that recognize only the carbohydrate portion of the glycoconjugate vaccine (Tcarb). These T cells were obtained by stimulation first in vivo with III-OVA and subsequently in vitro with III-TT. These findings suggested the possibility that Tcarbs contribute to the protection induced by GBSIII-OVA vaccine.
In a series of immunization experiments, we investigated the relative contributions of peptide-and carbohydrate-specific T cells to the induction of a carbohydrate-specific IgG response. Mice primed and boosted with GBSIII-OVA had GBSIII-specific IgG levels similar to those in mice primed with GBSIII-OVA and boosted with GBSIII-TT. Since GBSIII is the only shared antigen in the latter immunization group, this observation suggested that Tcarbs were primarily responsible for the GBSIII-specific adaptive immune response.
Demystifying T-cell activation mechanisms of glycoconjugate vaccines was a key step towards designing new-generation vaccines. We learned from our mechanistic studies that the most important feature of an ideal glycoconjugate vaccine would be enrichment for its glycan-peptide epitopes. Motivated by this information, we designed and synthesized a prototype new-generation glycoconjugate vaccine and tested it for immunogenicity and protective capacity in comparison with a traditional counterpart [5] . Our results showed that the newgeneration vaccine was strikingly more immunogenic and protective than the traditional glycoconjugate vaccine [5] . These findings strongly suggested that Tcarbs significantly contribute to the protection induced by a glycoconjugate vaccine.
It is well established that antibodies to CPSs mediate protection against challenge by encapsulated bacteria [4] . Therefore, from the standpoint of vaccine development, it is imperative to investigate whether Tcarbs can function as helper T (Th) cells to promote the secretion of antibody to CPSs by B cells, with consequent protection against bacterial infection. By shedding light on the important role played by this newly identified subset of CD4+ T cells, our study may represent the dawn of a new paradigm in T-cell biology that will lead to radical advances in the development of glycoconjugatebased vaccines against bacterial pathogens.
Glycopeptides and glycolipids
The adaptive immune system interacts with protein antigens through well-defined mechanisms [37] . Recently, important interactions of T cells with glycopeptide and glycolipid antigens have been discovered. Glycopeptides containing glycosidically linked mono-or oligosaccharides, which are generated from glycoproteins, or glycopeptides generated by coupling peptides with small oligosaccharides are recognized by CD4+ or CD8+ T cells [2, [38] [39] [40] [41] [42] [43] [44] [45] [46] . In addition, glycopeptides containing tumorassociated mono-or oligosaccharides are recognized by T cells [47, 48] . Recently, a number of synthetic vaccines comprising tumor-associated glycopeptides have been shown to elicit humoral immune responses to cancer cells expressing tumor-associated carbohydrates [49] .
Unique T cells expressing an invariant TCR as well as an NK marker, such as NK1.1 (in mice) or CD161 (in humans), are called invariant natural-killer T (iNKT) cells [50, 51] . Unlike conventional T cells, iNKT cells do not recognize peptide antigens presented by polymorphic MHCI or MHCII molecules, but rather recognize glycolipid antigens presented by the non-polymorphic MHCI-like molecule CD1d [1, [50] [51] [52] [53] [54] . Since the CD1d molecule is highly conserved between humans and mice, the mouse model can be used to predict CD1d-dependent iNKT-cell responses in humans [55] . ␣-Galactosylceramide (␣-GalCer) is a glycolipid antigen known to be specific for iNKT cells. Its two lipid tails fit tightly into a CD1d-binding groove, whereas its galactose head extends above the surface of the lipid-binding groove and thereby is exposed for recognition by the TCR of iNKT cells (Fig. 2) [56] [57] [58] . After presentation of ␣-GalCer by CD1d molecules, ␣-GalCer activates iNKT cells to rapidly produce large quantities of Th1 and Th2 cytokines -such as IFN-␥ and IL-4, respectively -and subsequently induces the activation of a cascade of various immunocompetent cells, including DCs, NK cells, B cells, and CD4+ and CD8+ T cells (Fig. 2 ) [51] . ␣-GalCer can therefore be used not only as potential direct therapy for cancer and for autoimmune and infectious diseases [59] [60] [61] [62] [63] [64] [65] [66] [67] [68] but also as an adjuvant to enhance the efficacy of various existing or future vaccines [69] [70] [71] [72] [73] . We have recently identified a novel ␣-GalCer analog, 7DW8-5, that stimulates iNKT cells more potently than does ␣-GalCer [74] . In addition, this glycolipid induces maturation and activation of DCs more strongly than does ␣-GalCer. The more potent biological activity of 7DW8-5 seems to be due to its greater binding affinity to CD1d molecules [74] . We found that, compared with its parental compound ␣-GalCer, 7DW8-5 displays more potent adjuvant activity on both DNA-based and adenoviral vector-based vaccines against malaria and HIV infection in mice [74, 75] . We are currently poised to move forward into phase 1 clinical trials using 7DW8-5 as an adjuvant.
Conclusions
Contrary to the traditional view suggesting that carbohydrates are T cell-independent antigens, we have come to understand that a lack of T-cell response to carbohydrates is due to a failure of these molecules to bind to MHCII, not to an inability of T cells to recognize presented carbohydrates. There are now numerous examples of carbohydrate recognition by T cells. The traditional view of glycoconjugate action [4, 13, 37] is based on the failure of most pure polysaccharides to elicit IgG memory in mice. This paradigm assumes that polysaccharide-specific IgG responses as well as B-and T-cell memory responses induced by glycoconjugate immunization are mediated by MHCII presentation of peptides (derived by protein processing) to the TCR. However, carbohydrates are processed in the endolysosome by reactive oxygen species or RNSs and, if bound to MHCII, are presented to and recognized by the TCR [3] [4] [5] [6] . Non-zwitterionic carbohydrates can be processed to smaller size in APC endosomes [6] but fail to bind directly to MHCII and therefore are not presented to T cells. In this review, we have discussed several examples of the presentation of carbohydratecontaining antigens to different subclasses of T cells. ZPSs bind directly to MHCII proteins and are presented to T cells. On the other hand, processing of glycoconjugate vaccines in the endosomes of APCs yields glycan-peptides whose peptide portions bind to MHCII so that glycan portions can be presented to T cells. In glycoconjugates, a high-molecular-weight glycan (∼10 kDa) is presented to T cells, and TCR recognition is not dependent on the peptide to which the carbohydrate is bound. Documentation of the existence of Tcarbs (T cells that recognize carbohydrates only) is a major step forward in our elucidation of how the adaptive immune system functions. GBSIII -the model polysaccharide antigen used in our studies -is a typical anionic CPS that does not bind to MHCII. Our study offers an explanation for adaptive immune activation by other glycoconjugate vaccines. However, the general applicability of our findings has yet to be tested with other glycoconjugate vaccines, and new repertoires of carbohydrate-recognizing T cells will need to be isolated.
The prevalence of a variety of complex biologic molecules in microbial organisms suggests that mammals evolved an immune system equipped to handle molecules other than proteins. The current understanding of the adaptive immune system is based primarily on protein antigens, although carbohydrates adorn the surfaces of organisms from all microbial kingdoms. If mammals evolved a major class of immune cells -T cells -that cannot recognize foreign carbohydrate structures, such a gap in immunity would seriously weaken the capacity to resist infection and therefore it is highly unlikely that such a gap exists.
Knowledge of the basic mechanisms governing carbohydrate presentation to T cells is essential to an understanding of human immunity to microbes. New insights into carbohydrate processing, presentation, and T-cell activation raise the possibility of novel carbohydrate-based vaccines and therapeutics with chemical and physical properties designed in light of specific information on antigen presentation.
